1 / 28

Continue Biologics Throughout Pregnancy

Continue Biologics Throughout Pregnancy. Uma Mahadevan MD Associate Professor of Medicine Co-Medical Director UCSF Center for Colitis and Crohn’s Disease. Key Points. Once pregnant, even with inactive disease, there is an increased risk of complications

xanti
Download Presentation

Continue Biologics Throughout Pregnancy

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Continue Biologics Throughout Pregnancy Uma Mahadevan MD Associate Professor of Medicine Co-Medical Director UCSF Center for Colitis and Crohn’s Disease

  2. Key Points Once pregnant, even with inactive disease, there is an increased risk of complications Moderate to severe disease increases risk Preterm birth is associated with significant infant mortality, morbidity and developmental delay Transfer of biologics across the placenta begins as soon as week 6 of gestation Interrupted anti-TNF therapy leads to antibody formation and loss of response

  3. Being in remission on low risk medication is the best option for a healthy pregnancy

  4. Increase in Preterm birth with moderate to high disease activity • Preterm birth (>37 wks gestation) • Leading cause of mortality in newborns • Higher rates CP, sensory deficits, learning disabilities, respiratory illness Norgard B, et al. Am J Gastroenterol. 2007;102:1947–1954.

  5. Cytokine spectrum in Pregnancy • Early: dominant proinflammatory profile • Embryo invades and damages maternal uterus to implant • Middle: • Decrease in proinflammatory cytokines. Mother, fetus, placenta in synchrony • Late: • Increase in proinflammatory cytokines to activate parturition

  6. PIANO:Pregnancy in Inflammatory Bowel Disease And Neonatal Outcomes • Patients classified by exposure to four groups of drugs taken b/w conception and delivery: • Unexposed: no immunomodulators/biologics • (mesalamine, steroids, antibiotics allowed) • Group A: AZA/6MP • +/- Unexposed medications • Group B: INF, ADA, CZP • +/- Unexposed medications • Group AB: Combination therapy • +/- Unexposed medications Mahadevan Gastroenterology 2012

  7. RESULTS

  8. Disease Activity by Trimester: CD % TRIMESTER AND MONTHS POSTPARTUM Two hospitalizations

  9. Disease Activity by Trimester: UC % TRIMESTER AND MONTHS POSTPARTUM No hospitalization

  10. Adverse Pregnancy Outcomes Adjusted for none/mild vs. mod/severe disease activity * P <0.05

  11. Adverse Pregnancy Outcomes: Crohn’s Disease * P <0.05 Adjusted for none/mild vs. mod/severe disease activity

  12. Adverse Pregnancy Outcomes:Ulcerative Colitis * P <0.05 Adjusted for none/mild vs. mod/severe disease activity

  13. Anti-TNF-alpha Therapies Certolizumab pegol PEG PEGylated humanized Fab′ fragment 2 × 20 kDa PEG Infliximab Adalimumab Fab′ Fab IgG1Fc Chimeric Human Monoclonal antibody Adapted from: Hanauer SB. Rev Gastroenterol Disord. 2004;4(Suppl. 3):S18-S24.

  14. Placental Transfer of IgG Ab • INF and ADA are IgG1 antibodies • Fc portion of IgG actively transported across placenta by specific neonatal FcR • Highly efficient transfer in 3rd T leads to elevated levels of drug in newborn B: Fetal r2=0.87, p<0.04 Wiley-Blackwell Publishing Ltd. Malek A, Evolution of maternofetal transport of immunoglobulins During human pregnancy. Am J Reprod Immunol 1996; 36(5):248-55. Image Courtesy of Sundana Kane MD

  15. Maternal IgG and IgA are potentially available to the embryo as early as the 6th week of gestation (coelomic fluid) • Maternal Ig present for the first 6 months of life to aid in fighting infection Jauniaux Human Reprod vol 10:12:3297-3300

  16. Placental Transfer • Infliximab: • Study of 10 mothers on IFX • In all cases, infant and cord IFX level were greater than mother. 6 months to clear • Adalimumab • Study of 10 mothers on ADA • In all cases, infant and cord ADA level was greater than mother. Up to 4 months to clear • ¾ pts who stopped ADA 35 days prior to delivery had a flare • Certolizumab • Study of 10 mothers • In all cases, infant and cord levels were less than 2 mcg/ml even if mom dosed the week of delivery Mahadevan U Clin Gastro Hep 2012 epub ahead of print

  17. Placental Transfer: Another view • 28 live births (17 IFX, 11 ADA) • Mean GA 39 [32-42] • Pts with active disease continued tx (5) • 10 pts on thiopurines, continued through pregnancy • IFX: 12/17 d/c week 18-27 • 14 restarted (week 8-27) • 1 allergic rxn, 2 changed to ADA: 3/12 (25%) • ADA: All 11 pts stopped week 22 • 2/11 relapsed – [18%] (CS wk 30; C section week 37) • all resumed therapy f/u 9 mos • 22 % (5/23) had a flare or need to change therapy postpartum. • Account for preterm birth, continuing thiopurines, presence of detectable levels even when discontinued <30 weeks. Zelinkova Clin Gastro Hep Oct 2012

  18. Infections Fatal case of disseminated BCG infection in an infant born to a mother on INF for Crohn’s disease 10 mg/kg q 8 weeks monotherapy Healthy boy delivered 36 wks. No Breastfeeding Did well until 3 months when received BCG Failure to thrive, died at 4.5 months Post-mortem: disseminated BCG Cheet K J of Crohn’s Colitis 2010

  19. Infections: Adjusted for Preterm Birth Mahadevan. Gastroenterologyh 2012

  20. Infections Adjusted for Preterm Birth: Excluding Certolizumab *This was not seen when infliximab and adalimumab were each excluded from the analysis.

  21. Infections by Exposure Group

  22. Timing of biologics • Debate: stop drug early or continue scheduled? • Last dose infliximab at week 32 weeks gestation • No real delay if patient gets next dose immediately after delivery (assume delivery around week 40 gestation) • Last dose adalimumab at week 36-38 • Stopping earlier may lead to flares • If needed, can continue throughout on schedule • Continue certolizumab throughout pregnancy • Avoid combination therapy with ADA/IFX • If mom flares, treat her! • No live virus vaccine for first 6 months for infants exposed to IFX or ADA during pregnancy • Never switch drugs during pregnancy purely for placental transfer issues Mahadevan U. Am J Gastroenterol. 2011 Feb;106(2):214-23

  23. Communicate with Interdisciplinary team • Obstetrician: • Most IBD medications are low risk in pregnancy (exception methotrexate) and can be continued during pregnancy and lactation • Pediatrician • No live virus vaccines in the first 6 months if infant exposed to infliximab or adalimumab in utero • All other vaccines can be given on schedule • Monitor for infections

  24. We do not recommend cessation of therapy in non-pregnant pts • WCOG Statement 1.17: • Pts with mod to severe luminal CD who have responded to induction anti-TNF should be considered for scheduled re-treatment…This strategy is more effective than episodic therapy for maintaining response. [EL 1b] • WCOG Statement 1.19: • Pts with UC refractory to conventional therapy which has responded to infliximab should best be considered for continuing therapy since scheduled re-treatment is effective for maintaining response and reducing the risk of colectomy [EL 1b] D’Haens Am J Gastroenterol 2011:106:199-212

  25. Summary • We teach all our patients the importance of compliance with biologic therapy • Risk of antibody formation • Risk of attenuated response • Pregnant women should not be different! • No increase in the risk of birth defects • No increase in infections in newborns except with combo therapy • Clear risk of increased adverse events with increased disease activity. • Postpartum is important too!

  26. Treat the patient , not your own fears …and if you are still not convinced…

  27. Consensus Statement • The risks and benefits of biologic therapy during the third trimester should be individually considered • Combination therapy with a biologic and immunomodulator should be avoided in pregnancy if possible • Certolizumab can be continued throughout pregnancy on schedule • Further studies are needed to determine the impact of significant levels of anti-TNF agents on newborn immune development and infection risk

More Related